You are here

REVERAGEN BIOPHARMA, INC.

Company Information
Address
155 GIBBS ST STE 433
ROCKVILLE, MD 20850-0394
United States



Information

UEI: NQA4J3L3E1Z4

# of Employees: 7


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales

    Amount: $3,352,543.00

    Abstract Vamorolone is a first-in-class dissociative steroidal drug that is being developed for Duchenne muscular dystrophy as a replacement for corticosteroid standard of care (prednisone, deflazacor ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  2. Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growth

    Amount: $224,998.00

    There is increasing interest in the use of biomarkers in clinical drug developmentwith much of thest Century Cures Act focused on encouraging this approachIdeallybiomarkers could provide and acute and ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health
  3. Definition of pharmacodynamic biomarkers for juvenile dermatomyositis for clinical trials

    Amount: $225,000.00

    Definition of pharmacodynamic biomarkers for juvenile dermatomyositis for clinical trials Juvenile dermatomyositisJDMis a rare disease with an incidence rate in the United States ofchildren per millio ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  4. Establishing a biomarker framework for feasibility studies of vamorolone in vasculitis

    Amount: $178,041.00

    Project Summary Abstract Antineutrophil cytoplasmic antibodyANCAassociated vasculitisAAVis a group of rare organ and lifethreatening multisystem diseases involving inflammation and destruction of smal ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  5. Pivotal trial of vamorolone in Duchenne muscular dystrophy

    Amount: $3,109,059.00

    Abstract ReveraGen BioPharma is a clinical stage drug development company that is developing vamoroloneVBPa first in class dissociative steroidal drugThe initial indication being tested is Duchenne mu ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  6. Effectiveness of VBP15, a dissociative steroidal analogue, on chronic inflammation in a mouse model of multiple sclerosis

    Amount: $253,802.00

    DESCRIPTION provided by applicant Glucocorticoids GCandapos s such as prednisolone are used frequently to induce remission and treat multiple sclerosis MS Despite effectiveness many GC medi ...

    STTRPhase I2016Department of Health and Human Services National Institutes of Health
  7. Phase IIa study of VBP for Duchenne muscular dystrophy

    Amount: $2,991,778.00

    DESCRIPTION provided by applicant ReveraGen BioPharma is a clinical stage drug development company that is developing VBP a novel dissociative steroidal class drug The initial indication for de ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  8. Effectiveness of VBP15, a dissociative steroidal analogue, on inflammation in a mouse model of arthritis

    Amount: $225,000.00

    DESCRIPTION provided by applicant Glucocorticoids GCandapos s such as prednisolone are used frequently to induce remission and treat rheumatoid arthritis RA Despite effectiveness many GC me ...

    STTRPhase I2015Department of Health and Human Services National Institutes of Health
  9. Effect of VBP15, a dissociative steroidal analogue, on intestinal epithelial repair processes in inflammatory bowel disease

    Amount: $225,000.00

    ? DESCRIPTION (provided by applicant): Glucocorticoids (e.g. prednisolone) are prescribed frequently to treat inflammatory bowel disease (IBD). Despite effectiveness, adverse side effects believed ...

    STTRPhase I2014Department of Health and Human Services National Institutes of Health
  10. Evaluation of VBP15 a dissociative steroidal analogue on pain and inflammation

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): The treatment of pain in Sickle Cell Disease (SCD) is challenging for both patients and providers and is associated with significant disparities in healt care deli ...

    STTRPhase I2014Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government